DT Cloud Star Acquisition Corporation (DTSQ) Company Overview

DT Cloud Star Acquisition Corporation is a Cayman Islands SPAC with no products, customers, or operating revenue. It seeks a private target and uses its listing and trust to bring that target public. Ordinary shares trade under DTSQ, with units and rights under DTSQU and DTSQR, as described in the latest Form 10-Q.

Why is a SPAC different from an operating company?

DTSQ is better understood as a temporary capital structure than as an operating enterprise. Before closing, the key assets are trust securities, while the key obligations are redemptions, transaction costs, sponsor advances, and deferred underwriting compensation. The decisive outcomes are closing probability, cash surviving redemptions, dilution, and post-combination listing and financing capacity.

DTSQ has no customer revenue. Pre-combination income comes mainly from trust-account interest and investment returns. Trust funds are reserved chiefly for redemptions or a completed combination, while corporate expenses rely on a much smaller cash balance and sponsor advances. This separation explains why a meaningful trust can coexist with almost no unrestricted cash.

Where does reported income come from?

Fiscal 2025 trust interest was $2.63 million, unrealized gains were $57,342, and operating-account interest was $6,205. These offset $557,174 of costs and produced $2.13 million of net income. The result mainly reflected yield on restricted transaction funds, as shown in the amended fiscal 2025 Form 10-K.

Why are trust assets not the same as operating liquidity?

At March 31, 2026, DTSQ had $1,656 of unrestricted cash, $928,408 of current liabilities, and $912,644 due to the sponsor. The $854,550 working-capital deficit creates dependence on sponsor support and transaction completion. Because further sponsor funding is not obligatory, the going-concern disclosure matters despite stable trust value.

What changed in the quarter ended March 31, 2026?

With the trust reduced by redemptions, Q1 2026 formation and operating costs of $238,316 plus $30,000 of administration produced a $268,316 operating loss. Trust interest of $103,332 and unrealized gains of $54,684 covered 58.9% of costs, leaving a $110,289 net loss. Q1 2025 had earned $630,284 when the trust was larger.

Why does the fiscal 2025 profit number need context?

Trust interest raises redemption value but does not establish recurring post-merger earnings. Pre-deal operating cash flow mainly reflects legal, audit, listing, and administrative costs. The relevant questions are sponsor funding capacity, future redemptions, and incremental transaction financing.

DTSQ’s strategic history is short, but each event materially changed the security’s economics. The timeline below connects the legal shell, public capital raise, redemption cycle, proposed biotechnology pivot, and current listing challenge.

Which turning points matter today?

1. November 2022
   The company was incorporated as Infinity Star Acquisition Corporation. This created the legal shell that would later pursue an IPO and business combination.
2. January 2024
   It changed its name to DT Cloud Star Acquisition Corporation, establishing the identity used for the public offering and current filings.
3. July 2024
   DTSQ completed a $69.00 million IPO of 6.90 million units and a $2.07 million private placement. The trust account, rights, founder shares, and deferred underwriting obligation all originate from this financing.
4. September 2024
   Unit holders could separately trade ordinary shares and rights. That separation created different payoff profiles: shares retained redemption rights, while rights depended on a completed deal.
5. October 2025
   Shareholders approved monthly extensions through October 26, 2026, requiring $75,000 per month. Approximately 5.25 million public shares were redeemed, sharply shrinking the trust and raising sponsor ownership concentration.
6. February 2026
   DTSQ signed the PrimeGen business combination agreement. The company moved from a target-search vehicle to a transaction-specific security tied to regenerative-medicine execution.
7. July 2026
   Nasdaq issued a delist determination over market-value and holder requirements. DTSQ timely requested a hearing, staying the scheduled suspension while the appeal proceeds.

The October 2025 extension preserved the shell through monthly sponsor-funded deposits, but redemptions left far less merger cash and increased sponsor control. The February 2026 deal announcement must therefore be read beside the redemption history; the target valuation is not cash available at closing.

How is the transaction structured?

DTSQ signed with PrimeGen on February 2, 2026. After two merger steps, PrimeGen survives as the purchaser’s wholly owned subsidiary. The transaction Form 8-K and the business combination agreement provide the governing terms.

What does PrimeGen bring to the investment story?

PrimeGen develops Triple Activated Mesenchymal Stem Cells and exosome-related therapies, with a lead focus on acute alcoholic hepatitis and acute liver failure. The official February 2026 transaction announcement says PrimeGen completed a pre-investigational-new-drug meeting with the U.S. Food and Drug Administration on December 17, 2025. It cautions that the FDA may reject an IND and preclinical results may not predict human outcomes.

The combination would create development-stage biotech exposure with contingent cash flows. A rigorous model needs audited financials, capitalization, clinical probabilities, trial spending, regulatory timing, intellectual property, pricing, reimbursement, and financing needs. The announced value cannot supply them.

What competes with this route to the public market?

DTSQ has no operating market share. Before closing, it competes with private rounds, IPOs, reverse mergers, and other acquisition vehicles. After closing, PrimeGen would compete for clinical talent, regulatory progress, manufacturing capacity, intellectual property, and capital. Current materials lack audited product-level disclosure for credible peer valuation.

SPAC securities carry different incentives. Public shares have redemption rights; rights depend on closing; founder shares had nominal historical cost; and private-placement units and extension advances put sponsor capital at risk. The claims are not homogeneous.

Where can dilution enter?

How much of the original public capital remains?

The $11.05 trust carrying value per redeemable share at March 31, 2026 is the clearest pre-close anchor. A merger model must then subtract transaction friction and incorporate redemptions, rights, warrants, new financing, and PrimeGen merger shares. Headline purchase price and closing cash are different quantities.

DT Cloud Star Management Limited controlled 1,931,900 ordinary shares, or 52.9%, as of February 17, 2026, giving the sponsor substantial voting influence. The fiscal 2025 filing also identifies several holders above 5%, but concentrated ownership does not remove redemption risk.

What does the holder mix signal?

How does governance work before and after the deal?

Sam Zheng Sun is CEO and chair, Kenneth Lam CFO and director, and Jiayi Liang COO. Independent directors staff the audit, compensation, and nominating/governance committees. Shaoke Li, Longjiao Li, and Chi Zhang chair those committees, respectively. Xunyong Zhou resigned on April 7, 2026 without disagreement, according to the company’s director-resignation Form 8-K.

Nasdaq had also notified DTSQ that it had fewer than 400 total holders and had granted an extension to October 5, 2026. The July determination says that extension is no longer available and treats the holder deficiency as another delisting basis. The July 20, 2026 Form 8-K says the hearing request stays suspension; it does not say the appeal has been won.

What must happen before the PrimeGen deal can close?

Additional risks include management conflicts, foreign-investment review, cybersecurity, legal claims, and deadline failure. PrimeGen adds intellectual-property, cell-manufacturing, regulatory, clinical, reimbursement, and financing uncertainty. These factors determine whether any post-close forecast is credible.

The dashboard changes at closing. Before closing, monitor trust value, liquidity, redemptions, deadlines, dilution, listing compliance, and transaction milestones. After closing, focus on clinical progress, cash runway, R&D burn, financing, and probability-adjusted commercial economics.

How strong is the current setup?

How should a DCF analyst frame DTSQ?

A sound model separates three values: the redeemable security before the vote, the probability-weighted transaction claim after dilution, and the post-close biotechnology enterprise. Combining them into one multiple hides the key risks. Full valuation should await the registration statement and audited PrimeGen information.

DT Cloud Star shows how SPAC structure can dominate analysis. Trust gives public shares a pre-close anchor, but it sits beside minimal unrestricted cash, a working-capital deficit, sponsor balances, heavy redemptions, dilution, and a Nasdaq appeal. PrimeGen adds biotechnology optionality together with clinical, regulatory, financing, governance, and listing uncertainty.

Support comes from a signed agreement, an identifiable target, a $1.49 billion base purchase-price framework, and $18.26 million in trust at March 31, 2026. Weaknesses are limited liquidity, heavy redemptions, the October deadline, Nasdaq uncertainty, and PrimeGen’s pre-commercial stage.

• Monitor the Nasdaq hearing and whether purchaser shares can satisfy the listing condition.
• Read the Form S-4 for audited PrimeGen financials, capitalization, risk factors, and pro forma cash.
• Recalculate trust value and redemption participation at the shareholder-vote date.
• Build a complete dilution bridge covering rights, warrants, sponsor securities, merger shares, and new financing.
• Track IND clearance and the first credible human clinical milestones rather than relying on preclinical descriptions.
• Test whether the combined company would have enough cash runway to reach the next value-creating regulatory milestone.